DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for prion disease — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePrion disease maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for prion disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
prion protein (Kanno blood group) (PRNP) — PRNP is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6LNI · 2.702 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
The 2016 genetic study of 16,025 prion disease cases, 60,706 population control exomes, and 531,575 genotyped individuals found that missense variants in the prion protein gene (PRNP) previously labelled as pathogenic are at least 30 times more common in the general population than expected from the prevalence of genetic prion disease. Some of this excess is due to benign variants being misclassified as pathogenic, but other variants do genuinely affect disease susceptibility, with lifetime risks ranging from less than 0.1% to approximately 100%. Truncating variants in PRNP have position-dependent effects, and true loss-of-function alleles were found in healthy older individuals, which the authors note supports the safety of therapeutic suppression of prion protein expression.
A 2008 systematic review of therapeutic interventions in human prion disease identified only one randomised trial. The review covered 140 published patient series and 33 studies describing 14 drugs, but ten of those drugs were reported in single studies of three or fewer patients, and one was reported for only two individual cases. The only reliable evidence came from the single randomised trial, which suggested that flupirtine may slow cognitive decline. For all other drugs examined in more detail, results were mixed, and survival of most treated patients fell within the ranges reported in untreated patient series. The review concluded that thirty years of clinical investigation had produced little progress in defining or evaluating potential treatments.
A 2012 study examined Brilliant Blue G (BBG), a P2X7 receptor antagonist, in cellular and mouse models of prion disease. BBG prevented accumulation of the pathogenic prion protein isoform in infected microglial and neural cells, with 50% inhibitory concentrations of 14.6 and 3.2 µM respectively. In mice with prion disease, BBG administration reduced accumulation of the pathogenic protein in the brain. However, it did not appear to alleviate disease progression compared to vehicle-treated controls. The authors state this implies a complex role of the P2X7 receptor in neuronal degeneration in prion diseases.
What is still missing is a structured framework for evaluating disease course and treatment in all patients, preferably within randomised controlled trials, as the 2008 review emphasised. The genetic findings highlight the difficulty of distinguishing truly pathogenic variants from low-penetrance risk factors, which complicates patient stratification for any future trial. The BBG study shows that reducing prion protein accumulation in the brain does not necessarily translate into clinical benefit, and no therapy has yet demonstrated a survival advantage in a controlled human trial. Funding for adequately powered, randomised studies in this rare disease remains a major barrier.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Science Translational Medicine · 2016 · 474 citations · open access
Quantifying prion disease penetrance using large population control cohorts
AbstractMore than 100,000 genetic variants are reported to cause Mendelian disease in humans, but the penetrance-the probability that a carrier of the purported disease-causing genotype will indeed develop the disease-is generally unknown. We assess the impact of variants in the prion protein gene (PRNP) on the risk of prion disease by analyzing 16,025 prion disease cases, 60,706 population control exomes, and 531,575 individuals genotyped by 23andMe Inc. We show that missense variants in PRNP previously reported to be pathogenic are at least 30 times more common in the population than expected on the basis of genetic prion disease prevalence. Although some of this excess can be attributed to benign variants falsely assigned as pathogenic, other variants have genuine effects on disease susceptibility but confer lifetime risks ranging from <0.1 to ~100%. We also show that truncating variants in PRNP have position-dependent effects, with true loss-of-function alleles found in healthy older individuals, a finding that supports the safety of therapeutic suppression of prion protein expression.
Systematic review of therapeutic interventions in human prion disease
AbstractBACKGROUND: The potential threat of a large outbreak of variant Creutzfeldt-Jakob disease initiated a proliferation of research into the understanding and treatment of human prion disease. However, clinical research is at an early stage with a pressing need for objective evaluation of treatments to inform the design of future studies. METHODS: We aimed to summarize existing research on outcomes of patients with prion disease, considering any published clinical study and patient series with data on disease progression. Methods were prespecified in a protocol and studies were identified from systematic searches of multiple sources. RESULTS: One randomized trial was identified. Many studies were flawed or poorly reported, and therefore interpreted cautiously. One hundred forty published patient series revealed wide ranges in disease duration for each of the prion diseases. Thirty-three studies described the use of 14 drugs, 10 which were reported in single studies of three or fewer patients and one which was reported for two individual cases. Effects of four drugs were examined in more detail, with mixed results. The only current reliable evidence is from the single randomized trial suggesting that flupirtine may slow cognitive decline. Based on published information identified by this review, survival of most treated patients is within the ranges reported in the untreated patient series. CONCLUSIONS: Thirty years of clinical investigation of patients with prion disease has resulted in little progress in either defining or evaluating potential treatments. Disease course and treatment of all patients must be evaluated within a structured framework, preferably within randomized controlled trials.
AbstractBACKGROUND: Prion diseases are fatal neurodegenerative disorders with no effective therapy currently available. Accumulating evidence has implicated over-activation of P2X7 ionotropic purinergic receptor (P2X7R) in the progression of neuronal loss in several neurodegenerative diseases. This has led to the speculation that simultaneous blockade of this receptor and prion replication can be an effective therapeutic strategy for prion diseases. We have focused on Brilliant Blue G (BBG), a well-known P2X7R antagonist, possessing a chemical structure expected to confer anti-prion activity and examined its inhibitory effect on the accumulation of pathogenic isoforms of prion protein (PrPres) in a cellular and a mouse model of prion disease in order to determine its therapeutic potential. PRINCIPAL FINDINGS: BBG prevented PrPres accumulation in infected MG20 microglial and N2a neural cells at 50% inhibitory concentrations of 14.6 and 3.2 µM, respectively. Administration of BBG in vivo also reduced PrPres accumulation in the brains of mice with prion disease. However, it did not appear to alleviate the disease progression compared to the vehicle-treated controls, implying a complex role of P2X7R on the neuronal degeneration in prion diseases. SIGNIFICANCE: These results provide novel insights into the pathophysiology of prion diseases and have important implications for the treatment.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
